We offer in-depth genomic profiling to identify somatic and germline mutations, single nucleotide polymorphisms (SNPs), copy number variations (CNVs), and complex structural variants (SVs) that drive cancer initiation, progression, and therapeutic resistance. Our high-accuracy sequencing platforms, including the Element Biosciences AVITI sequencer, combined with advanced bioinformatics pipelines, ensure unparalleled precision in detecting even rare mutations.
Our advanced mass spectrometry-based proteomics services enable the identification and quantification of thousands of proteins, including post-translational modifications. This provides a functional layer of insight into cancer biology, aiding in biomarker discovery, understanding signaling pathways, and assessing drug effects at the protein level.
We explore DNA methylation patterns and other epigenetic modifications that play critical roles in gene regulation and cancer development. Our Oxford Nanopore long-read sequencing technology allows for direct detection of base modifications, offering a comprehensive view of epigenetic landscapes.
Our world-renowned ribosome profiling (RIBO-seq) services provide a real-time snapshot of protein synthesis, bridging the gap between transcriptomics and proteomics. This is invaluable for identifying actively translated neoantigens, understanding translational dysregulation in cancer, and discovering novel therapeutic targets.
We identify and validate predictive and prognostic biomarkers for patient stratification, treatment response monitoring, and disease progression tracking. Our capabilities support the seamless transition of biomarkers from discovery to clinical validation.
We offer comprehensive services to support the discovery, evaluation, and optimization of CDx solutions, ensuring that the right treatment reaches the right patient. Our integrated approach leverages NGS, mass spectrometry, and qPCR to develop robust and clinically relevant biomarker assays.
Our highly sensitive MRD testing solutions, utilizing both NGS and qPCR technologies, enable the detection of very low levels of residual cancer cells after treatment. This is crucial for guiding personalized patient management and improving outcomes in oncology and hematology.
Our commitment to excellence is reflected in our adherence to globally recognized quality standards, including ISO 9001 and ISO 27001 certifications, GCLP standards, and operations in GMP-accredited laboratories. This ensures the reliability of our services for regulated environments.
